Immunochemotherapy

3 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-Oncologydiagnosis-to-treatment intervalFollicular lymphoma

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

By MedXY|Jun 30, 2026

Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

newsImmunochemotherapy

Immunochemotherapy

Latest news

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients